VCAM1 and epilepsy: Targeting of VCAM-1 with VCAM-MPIO and in vivo MRI has previously been demonstrated in preclinical models of numerous diseases, including neuroinflammation [37], cardiovascular disease [38], multiple sclerosis [39], epilepsy [40], and, most recently, brain metastasis [14,15,21].